Sung Bin Hong, Chief Executive Officer of Biomix Co., Ltd. agreed to acquire 40% stake in Biomix Co., Ltd. from Biotoxtech Co., Ltd. for KRW 5.4 billion.
January 16, 2020
Share
Sung Bin Hong, Chief Executive Officer of Biomix Co., Ltd. agreed to acquire 40% stake in Biomix Co., Ltd. from Biotoxtech Co., Ltd. (KOSDAQ:A086040) for KRW 5.4 billion on January 17, 2020. Sung Bin Hong will acquire 0.24 million shares. The consideration is paid as KRW 1.2 billion as deferred amount, KRW 1.2 billion will be paid on January 31, 2020, KRW 500 million will be paid on March 31, 2020 and KRW 2.5 billion will be paid on June 30, 2020. The deal was resolved by Board on January 17, 2020. The date of sales is June 30, 2020.
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
Sung Bin Hong, Chief Executive Officer of Biomix Co., Ltd. agreed to acquire 40% stake in Biomix Co., Ltd. from Biotoxtech Co., Ltd. for KRW 5.4 billion.
BIOTOXTECH CO., LTD. 
